Mortality associated with bacteremia due to colistin-resistant Klebsiella pneumoniae with high-level meropenem resistance: Importance of combination therapy without colistin and carbapenems

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 8, 2017, Pages

  Machuca, Isabel ^a   Gutiérrez Gutiérrez, Belén ^b,c   Gracia Ahufinger, Irene ^a   Rivera Espinar, Francisco ^a   Cano, Ángela ^a   Guzmán Puche, Julia ^a   Pérez Nadales, Elena ^a   Natera, Clara ^a   Rodríguez, Marina ^a   León, Rafael ^a   Castón, Juan J ^a   Rodríguez López, Fernando ^a   Rodríguez Baño, Jesús ^b,c   Torre Cisneros, Julián ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Bacteremia; Carbapenems; Colistin; Klebsiella pneumoniae; Mortality

Indexed keywords

CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; MEROPENEM; PENICILLIN DERIVATIVE; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE; THIENAMYCIN DERIVATIVE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BLOOD CULTURE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMORBIDITY; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MORTALITY RATE; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPTIC SHOCK; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG EFFECT; GENETICS; KLEBSIELLA INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; COLISTIN; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FOSFOMYCIN; GENTAMICINS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; PROSPECTIVE STUDIES; SHOCK, SEPTIC; THIENAMYCINS;

EID: 85026408119     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00406-17     Document Type: Article

References (31)

1. Endimiani A, Depasquale JM, Forero S, Perez F, Hujer AM, Roberts-Pollack D, Fiorella PD, Pickens N, Kitchel B, Casiano-Colon AE, Tenover FC, Bonomo RA. 2009. Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother 64:1102–1110. https://doi.org/10.1093/jac/dkp327.
2. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, Shrestha NK, Fraser TG, van Duin D. 2011. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis 69:357–362. https://doi.org/10.1016/j.diagmicrobio.2010.10.013.
3. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. 2008. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29:1099–1106. https://doi.org/10.1086/592412.
4. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56: 2108–2113. https://doi.org/10.1128/AAC.06268-11.
5. Saidel-Odes L, Polachek H, Peled N, Riesenberg K, Schlaeffer F, Trabelsi Y, Eskira S, Yousef B, Smolykov R, Codish S, Borer A. 2012. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol 33:14–19. https://doi.org/10.1086/663206.
6. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55: 943–950. https://doi.org/10.1093/cid/cis588.
7. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. 2012. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 25:682–707. https://doi.org/10.1128/CMR.05035-11.
8. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A. 2011. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17:1798–1803. https://doi.org/10.1111/j.1469-0691.2011.03514.x.
9. Rodriguez-Bano J, Cisneros JM, Cobos-Trigueros N, Fresco G, Navarro-San Francisco C, Gudiol C, Horcajada JP, Lopez-Cerero L, Martinez JA, Molina J, Montero M, Pano-Pardo JR, Pascual A, Pena C, Pintado V, Retamar P, Tomas M, Borges-Sa M, Garnacho-Montero J, Bou G, Study Group of Nosocomial Infections of the Spanish Society of Infectious Diseases. 2015. Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enferm Infecc Microbiol Clin 33:337.e1–337.e21. https://doi.org/10.1016/j.eimc.2014.11.009.
10. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A. 2014. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322–2328. https://doi.org/10.1128/AAC.02166-13.
11. Gutierrez-Gutierrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Pano-Pardo JR, Venditti M, Tumbarello M, Daikos G, Canton R, Doi Y, Tuon FF, Karaiskos I, Perez-Nadales E, Schwaber MJ, Azap OK, Souli M, Roilides E, Pournaras S, Akova M, Perez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodriguez-Bano J, REIPI/ESGBIS/INCREMENT Investigators. 2017. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis https://doi.org/10.1016/S1473-3099(17)30228-1.
12. Giani T, Arena F, Vaggelli G, Conte V, Chiarelli A, Henrici De Angelis L, Fornaini R, Grazzini M, Niccolini F, Pecile P, Rossolini GM. 2015. Large nosocomial outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae traced to clonal expansion of an mgrB deletion mutant. J Clin Microbiol 53:3341–3344. https://doi.org/10.1128/JCM.01017-15.
13. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH. 2016. Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63:1615–1618. https://doi.org/10.1093/cid/ciw636.
14. Daikos GL, Markogiannakis A. 2011. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 17:1135–1141. https://doi.org/10.1111/j.1469-0691.2011.03553.x.
15. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. 2012. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect 18:439–448. https://doi.org/10.1111/j.1469-0691.2012.03823.x.
16. Del Bono V, Giacobbe DR, Marchese A, Parisini A, Fucile C, Coppo E, Marini V, Arena A, Molin A, Martelli A, Gratarola A, Viscoli C, Pelosi P, Mattioli F. 2017. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: should we get to the PK/PD root of the paradox? Virulence 8:66–73. https://doi.org/10.1080/21505594.2016.1213476.
17. Shields RK, Nguyen MH, Potoski BA, Press EG, Chen L, Kreiswirth BN, Clarke LG, Eschenauer GA, Clancy CJ. 2015. Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia. Antimicrob Agents Chemother 59:1797–1801. https://doi.org/10.1128/AAC.03894-14.
18. Wiskirchen DE, Crandon JL, Nicolau DP. 2013. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents 41:582–585. https://doi.org/10.1016/j.ijantimicag.2013.02.015.
19. Sbrana F, Malacarne P, Viaggi B, Costanzo S, Leonetti P, Leonildi A, Casini B, Tascini C, Menichetti F. 2013. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 56: 697–700. https://doi.org/10.1093/cid/cis969.
20. Papadimitriou-Olivgeris M, Marangos M, Christofidou M, Fligou F, Bartzavali C, Panteli ES, Vamvakopoulou S, Filos KS, Anastassiou ED. 2014. Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit. Scand J Infect Dis 46:642–648. https://doi.org/10.3109/00365548.2014.923106.
21. Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, Pontes-Moreno A, Lopez-Cerero L, Pascual A, Natera C, Rodriguez M, Salcedo I, Rodriguez-Lopez F, Rivero A, Rodriguez-Bano J. 2015. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother 70:905–913. https://doi.org/10.1093/jac/dku432.
22. Michail G, Labrou M, Pitiriga V, Manousaka S, Sakellaridis N, Tsakris A, Pournaras S. 2013. Activity of tigecycline in combination with colistin, meropenem, rifampin, or gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother 57:6028–6033. https://doi.org/10.1128/AAC.00891-13.
23. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, STROBE Initiative. 2007. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8.
25. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. 2016. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801–810. https://doi.org/10.1001/jama.2016.0287.
26. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. 1989. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 87:540–546. https://doi.org/10.1016/S0002-9343(89)80611-4.
27. Horan TC, Andrus M, Dudeck MA. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309–332. https://doi.org/10.1016/j.ajic.2008.03.002.
28. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ. 2002. Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137:791–797. https://doi.org/10.7326/0003-4819-137-10-200211190-00007.
29. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS. 2003. 2001 SCCM/ ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250–1256. https://doi.org/10.1097/01.CCM.0000050454.01978.3B.
30. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). 2000. EUCAST definitive document E.DEF 3.1, June 2000: determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clin Microbiol Infect 6:509–515. https://doi.org/10.1046/j.1469-0691.2000.00142.x.
31. Lopez-Cerero L, Egea P, Gracia-Ahufinger I, Gonzalez-Padilla M, Rodriguez-Lopez F, Rodriguez-Bano J, Pascual A. 2014. Characterisation of the first ongoing outbreak due to KPC-3-producing Klebsiella pneumoniae (ST512) in Spain. Int J Antimicrob Agents 44:538–540. https://doi.org/10.1016/j.ijantimicag.2014.08.006.